Advertisement

Topics

REVOTAR Biopharmaceuticals AG Company Profile

13:15 EDT 18th September 2018 | BioPortfolio

Revotar Biopharmaceuticals AG is a privately owned, independent German biopharmaceutical company located in Hennigsdorf close to Berlin. Revotar develops innovative small molecule anti-inflammatory drugs for indications such as asthma, psoriasis, sepsis, COPD and other inflammatory indications.Revotar was founded in 2000. The Company was endowed from the start with the asset bimosiamose, an innovative proprietary drug product (selectin antagonist) for the therapy of a variety of inflammatory disorders.
Our advanced drug candidate bimosiamose has passed three Phase II a (proof of concept) clinical trials in Asthma and Psoriasis.
Within our business build-up strategy, we focus on a subsegment of the R&D value chain of innovative drug discovery and drug development which can be managed with the resources of a start-up company. This subsegment ranges from validated targets, lead generation, lead optimization, preclinical development to Phase I/II clinical development (proof of concept/efficacy in man). After having successfully passed these stages Revotar is looking for strategic partners for co-development as well as licensee.
This business model offers at the same time future opportunity for growth towards a fully integrated pharmaceutical company (FIPCO).

Location

Neuendorfstrasse 24a
Hennigsdorf
16761
Germany

Contact

Phone: 49 (0)3302 / 202 50 10
Fax: 49 (0)3302 / 202 50 11
Email: info@revotar-ag.de


News Articles [197 Associated News Articles listed on BioPortfolio]

Transgene and Tasly Biopharmaceuticals Conclude Strategic Agreements for the Rights of Transgene's Virus-Based Immunotherapies TG6002 and TG1050 in Greater China

Transgene to receive $48 million paid in newly created Tasly Biopharmaceuticals shares Deals give Tasly Biopharmaceuticals full control over Greater China1 development and commercial rights to the...

Akebia Therapeutics to merge with Keryx Biopharmaceuticals

US-based biopharmaceutical firm Akebia Therapeutics has signed a definitive agreement to merge with Keryx Biopharmaceuticals to form a fully integrated...Read More... The post Akebia Therapeutics to m...

Eiger BioPharmaceuticals completes enrolment in Prevent trial

Eiger BioPharmaceuticals has completed patient enrolment in the Phase ll Prevent trial evaluating the safety and durability of subcutaneous (SC)...Read More... The post Eiger BioPharmaceuticals comple...

5 Top Weekly NASDAQ Biotech Stocks: Eiger BioPharmaceuticals Leads with 81.62 Percent

Eiger BioPharmaceuticals, Arqule, Galectin Therapeutics, MEI Pharma and BioDelivery Sciences were last week's top gainers on the NASDAQ. The post 5 Top Weekly NASDAQ Biotech Stocks: Eiger BioPharmace...

Alder BioPharmaceuticals, Inc. (ALDR) to Present at the Canaccord Genuity 38th Annual Growth Conference

Alder BioPharmaceuticals® to Present at the Canaccord Genuity 38th Annual Growth Conference Alder BioPharmaceuticals, Inc. (ALDR), a biopharmaceutical company focused on developing novel therapeutic ...

New international partnership promises great potential for next-generation biopharmaceuticals

There are a multitude of challenges associated with the production of next-generation biopharmaceuticals and vaccines. The Austrian Centre of Industrial Biotechnology and the BOKU - University of Natu...

Sirona Biochem Receives US$500,000 Payment from Wanbang Biopharmaceuticals

Sirona Biochem (TSXV:SBM) has announced it has received the US$500,0000 payment from Wanbang Biopharmaceuticals for approval by the China and Food Drug Administration for the company’s Phase I c...

Akebia Therapeutics and Keryx Biopharmaceuticals to Merge

Akebia Therapeutics (NASDAQ:AKBA) and Keryx Biopharmaceuticals (NASDAQ:KERX) today announced that the companies signed, and the boards of directors of both companies have unanimously approved, a defin...

Drugs and Medications [1 Associated Drugs and Medications listed on BioPortfolio]

Thrombin human [Ethicon, Inc]

These highlights do not include all the information needed to use EVITHROM safely and effectively. See full prescribing information for EVITHROM.EVITHROM, Thrombin, Topical (Human)For Topical Use Only...

PubMed Articles [38 Associated PubMed Articles listed on BioPortfolio]

Surfactants as Stabilizers for Biopharmaceuticals: An Insight into the Molecular Mechanisms for Inhibition of Protein Aggregation.

Surfactants are common stabilizers, often added to biopharmaceuticals formulations, but the mechanisms at the basis of their activity are unclear. The aim of this work is to provide insight into the m...

Next Generation Biopharmaceuticals: Product Development.

Therapeutic proteins show a rapid market growth. The relatively young biotech industry already represents 20 % of the total global pharma market. The biotech industry environment has traditionally bee...

Characterisation of protein aggregation with the Smoluchowski coagulation approach for use in biopharmaceuticals.

Protein aggregation is a field of increasing importance in the biopharmaceutical industry. Aggregated particles decrease the effectiveness of the drug and are associated with other risks, such as incr...

Development and validation of a bioassay to evaluate binding of adalimumab to cell membrane-anchored TNFα using flow cytometry detection.

Physicochemical and structural properties of proteins used as active pharmaceutical ingredients of biopharmaceuticals are determinant to carry out their biological activity. In this regard, the assays...

Harnessing the power of an expanded genetic code toward next-generation biopharmaceuticals.

Synthetic biology has been revolutionizing the biopharmaceutical industry from drug discovery, clinical development to the manufacturing of biopharmaceuticals. As one of its most promising areas, gene...

Clinical Trials [2 Associated Clinical Trials listed on BioPortfolio]

Nicotine Vaccination and Nicotinic Receptor Occupancy

This is a molecular imaging research study designed to examine how much nicotine gets into the brain before and after vaccination with NicVAX, a nicotine vaccine developed by Nabi Biopharm...

A Phase III Clinical Trial of a Haemophilus Influenzae Type b (Hib) Conjugate Vaccine

Haemophilus influenza type b (Hib) remains a serious global health threat associated with high mortality and morbidity in young children. In China, The overall impact of Hib-related infect...

Companies [186 Associated Companies listed on BioPortfolio]

REVOTAR Biopharmaceuticals AG

Revotar Biopharmaceuticals AG is a privately owned, independent German biopharmaceutical company located in Hennigsdorf close to Berlin. Revotar develops innovative small molecule anti-inflammatory dr...

Itero Biopharmaceuticals, Inc.

Itero Biopharmaceuticals, Inc. is a specialty biopharmaceutical company focused on the development and commercialization of protein therapeutics that offer significant clinical an...

Bechtel Group Biopharmaceuticals Production

Design, construction, and validation of facilities for production of human biopharmaceuticals utilizing either fermentation or cell culture, facilities maintenance & operation for the virtual organiza...

BioRexis Pharmaceutical Corporation

BioRexis™ develops and produces novel biopharmaceuticals with superior pharmacology using efficient manufacturing systems. Many biopharmaceuticals face difficulties in development and commercializat...

Inspiration Biopharmaceuticals, Inc.

Inspiration Biopharmaceuticals is dedicated exclusively to developing treatments for hemophilia, with a primary mission to broaden access to care, including prophylactic therapy, and improve the treat...

More Information about "REVOTAR Biopharmaceuticals AG" on BioPortfolio

We have published hundreds of REVOTAR Biopharmaceuticals AG news stories on BioPortfolio along with dozens of REVOTAR Biopharmaceuticals AG Clinical Trials and PubMed Articles about REVOTAR Biopharmaceuticals AG for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of REVOTAR Biopharmaceuticals AG Companies in our database. You can also find out about relevant REVOTAR Biopharmaceuticals AG Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

Psoriasis
Psoriasis is a common skin condition affecting 2-3% of the population of the United Kingdom, where the skins replacement process is sped taking 2-6 days instead of the usual 21 - 28 days for the replacement of skin cells. Patients experience an accumulat...


Corporate Database Quicklinks



Searches Linking to this Company Record